V březnu se zúčastníme celoslovenské genetické konference, která se koná 16. - 17. 3. 2022 v hotelu Turiec ve slovenském Martině. Konferenci pořádá Slovenská společnost lékařské genetiky a je již trad...
VíceNavštivte nás na Genetické konferenci pořádané Genetickou společností Gregora Mendela. Tento rok proběhne v termínu 5. - 7. 10. společně s konferencí Genetické dny, jež se konají ve dvouletých interva...
VícePřijďte se na nás podívat na Celostátní sjezd Společnosti lékařské genetiky a genomiky ČLS JEP a 55. výroční cytogenetickou konferenci, jež se koná ve Wellness Hotelu Step 15. a 16. září. Rádi se s Vá...
VíceKRAS/NRAS/BRAF Mutations Detection Kit
Detection of 17 KRAS mutations (exons 2, 3 and 4), 13 NRAS mutations (exons 2, 3 and 4) and six BRAF V600 mutations (exon 15)
KRAS, NRAS and BRAF genes are the key molecules in the downstream signaling pathway of epidermal growth factor receptor (EGFR). These pathways control cell proliferation,differentiation and apoptosis.Frequency of KRAS, NRAS and BRAF mutations in colorectal cancer are 36~40%, 1~6% and 8~15% respectively. Most frequent mutations occur in exons 2, 3 and 4 of RAS gene, and in codon 600 of BRAF gene.
KRAS mutations and NRAS mutations predict a lack of response to cetuximab (Erbitux®) and panitumumab (Vectibix®) therapy in colorectal cancer (CRC).[1]A number oflarge studies[2][3] have shown that cetuximab has significant efficacy in mCRCpatients with RAS wild-type tumors.And mutations in BRAF gene are a strong prognostic marker. Clinical data has shown that colorectal cancer patients with mutant BRAF gene are less likely to response to EGFR-TKIs therapy. NCCN Clinical Practice Guideline for colon cancer clearly indicates that all patients with metastatic colorectal cancer should be determined of tumor RAS (KRAS/NRAS) and BRAF genes status.
The AmoyDx®KRAS/NRAS/BRAFMutationsDetection Kit is a real-time PCR test intended for qualitative detection of 17 KRASmutations(exons 2, 3 and 4),13 NRASmutations(exons 2, 3 and 4)and six BRAF V600mutations(exon 15).
Technological Principles
The kit uses novel, patented primers and probes to detect mutations in a real-time PCR assay.
The mutant DNA is amplified accurately by the specific primers, and detected by the novel probes.
Highly Specific primers and probes, and a highly validated procedure based on Taq DNA polymerase contribute to outstanding assay sensitivity and selectivity.